The 18th patient was treated for phase one, and the patient returned to the trial for an additional set of injections.
“In some patients, it appears that the disease is no longer progressing, but it is too early to know if the result from that small number of patients is meaningful,” said Eva Feldman, MD, PhD, the principal investigator of the trial and an unpaid consultant to Neuralstem.
More Articles on Stem Cells:
11 Sports Medicine Surgeons Researching Biologics
Grayslake Suite of Illinois Bone & Joint Institute Slated to Open Soon
Institute of Regenerative and Molecular Orthopedics Hopes to Pioneer Stem Cell Harvesting
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
